🔴 Femasys is trading 10.68% down in pre-market after an August 19 rally

Femasys is trading at $2.42, down -10.68%, following a sharp August 19 rally after the FDA approved a modular PMA pathway for FemBloc.

• The decision allows staged regulatory review but does not authorize U.S. marketing.
• FemBloc remains investigational pending clinical results.
• Available coverage identifies no separate August 20 catalyst; the decline may reflect post-rally volatility rather than confirmed negative news.